| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
This study aims to examine the role of SMF1 in SCLC.First, the histological stain of clinical and pathological human samples revealed that SMF1 was highly expressed in SCLC compared with lung adenocarcinoma and squamous cell carcinoma. Moreover, SMF1 was highly phosphorylated in NSCs, and similarly, it was highly phosphorylated in SCLC. Thus, I created a stable cell line with loss of SMF1 by introducing SMF1-shRNA into a culture of SCLC using the in vitro electroporation method (Fig.3), and examined the nature of cancer in the absence of SMF1 by implanting the cells under the skin of high immunodeficient mice. As a result, in the absence of SMF1, the proliferative ability of the cancer became low, and the size decreased. Additionally, staining of the stable cell line with loss of SMF1 with anti-CD 133 antibody, which is a cancer stem cell marker, and the analysis using flow cytometry revealed that the number of CD 133 positive cells reduced compared with a controll cell line.
|
